Large Study Links Smoking to Pancreatic Cancer

BY MITCHEL L. ZOLER
Philadelphia Bureau

HOLLYWOOD, FLA. — Cigarette smoking plays a role in both the initiation and progression of pancreatic cancer, based on an analysis of more than 18,000 patients with the disease.

"To our knowledge, this is the first compelling evidence for a role of cigarette smoking early in the neoplastic transformation of the pancreas," Randall E. Brand, M.D., said at a symposium on gastrointestinal cancers sponsored by the American Society of Clinical Oncology.

"Eventually, we will use screening tests for pancreatic cancer, and people who smoke should be screened at an earlier age than nonsmokers," said Dr. Brand, a gastroenterologist at Northwestern University in Chicago.

The study used data in the Cancer Information Resource File from more than 350 U.S. teaching and community hospitals. The database included records for 18,346 people with pancreatic cancer who had information on smoking history in their files.

Genes May Affect Pancreatic Cancer Risk in Diabetics

LAS VEGAS — Genetic variations in two major antioxidant enzymes may increase the risk of pancreatic cancer in people with diabetes mellitus, according to preliminary data presented at the annual meeting of the North American Association for the Study of Obesity.

In an ongoing, hospital-based, case-control study, pancreatic cancer risk was nearly four times higher (odds ratio, 3.8) in diabetic patients who had a catalase variant. The risk was nearly six times higher (odds ratio, 5.7) if they had a variant of superoxide dismutase. The patient population included both type 1 and type 2 diabetics; most had type 2 diabetes, said Manal M. Hassan, M.D., a molecular epidemiologist at the University of Texas M.D. Anderson Cancer Center, Houston.

Type 2 diabetes is a significant risk factor for pancreatic cancer. The researchers hypothesized that an impaired defense against oxidative stress makes some patients more susceptible to pancreatic cancer.

The study has so far compared 556 confirmed cases of adenocarcinoma of the pancreas with 344 spouses of M.D. Anderson patients who had other forms of cancer. The goal is to enroll 800 pancreatic cancer cases, Dr. Hassan said.

The researchers hope to develop a model to identify patients who are most susceptible. "A large-scale study, to assess the interaction between our findings and obesity indicators such as weight change, is warranted," the researchers concluded at the meeting, which was cosponsored by the American Diabetes Association.

—Jane Salodof MacNeil

The analysis split the patients into four categories: never smokers, prior smokers, current smokers, and ever smokers (current and prior smokers combined). Current smokers were considered to be people who smoked cigarettes either at the time their pancreatic cancer was first diagnosed or within 1 year preceding their diagnosis.

The mean age at diagnosis was 63 years among current smokers, 67 years among ever smokers, 70 years among prior smokers, and 73 years among never smokers.

The finding that prior smokers developed pancreatic cancer at a younger age than never smokers suggests that smoking contributes to the initiation of pancreatic cancer. And the finding that current smokers developed pancreatic cancer at an even younger age suggests that smoking also plays a role in disease progression, Dr. Brand said.

"We were surprised by the magnitude of the effect. We had anticipated that it would be a few years at most, not the dramatic 7 to 10 years that we saw," Dr. Brand said at the symposium, also sponsored by the American Gastroenterological Association, the American Society for Therapeutic Radiation and Oncology, and the Society of Surgical Oncology.

It is not known how cigarette smoke affects the pancreas. The immune effects of smoking may mediate development of pancreatic cancer, and a carcinogen present in tobacco smoke may accumulate in the pancreas.

Finds inner peace, but still feels the burn.

Needs help that fits her routine.

Acid-related disorders can affect individuals differently. That's what drives PREVACID to make sure we help you treat your patients' individual needs. So, while PREVACID capsules deliver effective treatment as indicated, we continue to develop other formulations to address unique situations. Quite simply, at PREVACID, we are committed to helping you give your patients the treatment they need.

Ask your PREVACID sales rep about our treatment options.



Important Safety and Other Information

PREVACID indications include the short-term treatment of symptomatic GERD. Individual results may vary.

- The most frequently reported adverse events with PREVACID in adults were diarrhea (3.8%), abdominal pain (2.1%), and nausea (1.3%).
- Symptomatic response to therapy does not preclude the presence of gastric malignancy. PREVACID formulations are contraindicated in patients with known hypersensitivity to any component of the formulation.

See adjacent page for brief summary of prescribing information.

©2005 TAP Pharmaceutical Products Inc. 2005-030-06365 02/05